Meet Ferring Pharmaceuticals, a Gold Sponsor of our Having IMPACTT: Advancing Microbiome Research Symposium on Sept 22-24, 2025
Helping People Live Better Lives
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people build healthy families and live better lives. Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology.
Our Vision – Microbiome
(Break the C. diff Cycle | Ferring Pharmaceuticals)
We are committed to unlock the power of the gut microbiome to develop innovative microbiome-based therapeutics that help people live better lives.
We begin by restoring hope for people trapped in the debilitating cycle of recurrent Clostridioides difficile infection and will continue to innovate and expand our focus, advancing as scientific and commercial leaders in selected diseases with significant unmet medical needs.
On March 6, 2025 Ferring Inc. received Health Canada approval for REBYOTA (fecal microbiota, live)
See press release
Health Canada issued a Notice of Compliance, approving REBYOTA® (fecal microbiota, live), a novel first-in-class microbiome-restoration therapy indicated for the prevention of recurrence of C. difficile infection (C. diff) in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff.
Follow us on Twitter/X, LinkedIn, YouTube, Facebook, and Instagram
